-
Views
-
Cite
Cite
Masafumi Nogimori, Cross-boundary Cancer Studies at the University of Tokyo: Astellas in Asia: Challenge for Cancer, Japanese Journal of Clinical Oncology, Volume 44, Issue suppl_1, February 2014, Pages i60–i64, https://doi.org/10.1093/jjco/hyt218
- Share Icon Share
Extract
LECTURER PROFILE
Representative Director, Chairman of the Board, Astellas Pharma, Inc., a research and development oriented pharmaceutical company headquartered in Tokyo, Japan. At Astellas Pharma, Inc., Mr Masafumi Nogimori has served as President and CEO from 2006 to 2011, Executive Vice President from 2005 to 2006 and has been Representative Director since 2005. Prior to the April 2005 merger between Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd., which created Astellas, Mr Nogimori was Corporate Executive Vice President of Global Strategy at Fujisawa. Upon joining Fujisawa in 1970, Mr Nogimori engaged in Licensing, Business Development and various planning functions for about 30 years. He also led businesses at regional headquarters, in the USA, as Vice President, Business Development at Fujisawa USA, Inc. from 1993 to 1995, and in Germany, as President at Fujisawa GmbH from 1998 to 2001. Mr. Nogimori has a Bachelor of Pharmaceutical Sciences from the University of Tokyo.